IDEAYA Biosciences reported a strong quarter of clinical execution and pipeline expansion, with significant progress in its darovasertib trials and IND clearances for new ADC candidates. The company ended the year with substantial cash reserves, positioning it to fund operations into 2030.
Cash, cash equivalents, and marketable securities of approximately $1.05 billion as of December 31, 2025, expected to fund operations into 2030.
positiveCollaboration revenue increased to $10.9 million for Q4 2025 from $7.0 million in Q4 2024, driven by the Servier license agreement.
positiveIND filings for IDE034 (B7H3/PTK7 bispecific TOP1 ADC) and IDE574 (KAT6/7 dual inhibitor) were cleared by the FDA.
positiveFull enrollment of 437 patients in the OptimUM-02 Phase 2/3 registrational trial for darovasertib and crizotinib combination completed.
positiveNet loss for Q4 2025 was $83.3 million, compared to $130.3 million in Q4 2024, indicating continued significant operating losses.
negativeResearch and development expenses for Q4 2025 were $86.6 million, an increase from $140.2 million in Q4 2024, primarily due to a $75.0 million upfront payment in the prior year, but still representing substantial ongoing investment.
attentionGeneral and administrative expenses increased to $18.8 million in Q4 2025 from $11.0 million in Q4 2024, driven by higher personnel, consulting, and legal fees.
attentionNet loss for the full year 2025 was $113.7 million, compared to $274.5 million in 2024, still reflecting substantial operating losses.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
We had a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities.
The key highlights include completing full enrollment of 437 patients in OptimUM-02, our Phase 2/3 registrational trial in first line HLA*A2-negative mUM, submission of IND filings for IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC, and IDE574, a KAT6/7 dual inhibitor, and continued build out of our U.S. commercial organization in anticipation of our upcoming topline PFS results.
Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials across all stages of uveal melanoma by H1 ’26.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.